Edwards Lifesciences Corporation

NYSE:EW Stock Report

Market Cap: US$46.9b

Edwards Lifesciences Future Growth

Future criteria checks 1/6

Edwards Lifesciences is forecast to grow earnings and revenue by 16.7% and 8.7% per annum respectively. EPS is expected to grow by 17.5% per annum. Return on equity is forecast to be 16.7% in 3 years.

Key information

16.7%

Earnings growth rate

17.48%

EPS growth rate

Medical Equipment earnings growth16.0%
Revenue growth rate8.7%
Future return on equity16.72%
Analyst coverage

Good

Last updated14 May 2026

Recent future growth updates

Recent updates

Narrative Update • May 12

EW: 2026 LAA Closure Entry Will Drive Future Upside Repricing

Edwards Lifesciences' updated analyst price target edges higher by about $0.20, reflecting analysts' slightly stronger assumptions on long term revenue growth, profit margins, and a modestly lower discount rate, even as recent Street research showed a mix of price target raises and cuts across firms such as Barclays, Truist, Evercore ISI, BTIG, Baird, BofA, Mizuho, UBS, Goldman Sachs, and Piper Sandler. Analyst Commentary Recent research shows a split view on Edwards Lifesciences, with some firms lifting price targets and others trimming them or turning more cautious.
Narrative Update • Apr 28

EW: 2026 LAA Closure Opportunity Will Support Future Upside Repricing

Analysts have inched their blended price target for Edwards Lifesciences higher by roughly $0.04 to about $96.96. This reflects updated assumptions around slightly lower modeled revenue growth, a modestly higher discount rate, a firmer profit margin outlook, and a somewhat lower future P/E multiple after recent mixed target moves across the Street.
Narrative Update • Apr 10

EW: 2026 LAA Closure Expansion Will Support Upside Repricing

Analysts have nudged their fair value target for Edwards Lifesciences slightly lower to about $96.93, reflecting updated assumptions on discount rates, revenue growth, profit margins, and future P/E following a mix of recent price target cuts and raises across the Street. Analyst Commentary Recent research takes on Edwards Lifesciences point to a mixed but generally engaged stance from the Street, with both upgrades and target changes feeding into the updated fair value view.
Narrative Update • Mar 27

EW: 2026 TAVR Indication Expansion And LAA Closure Plans Will Drive Upside

Analysts have made a modest upward adjustment to Edwards Lifesciences' intrinsic value estimate, with the fair value moving to $97.12. This is supported by research that highlights the company's expanding left atrial appendage closure offerings, its updated 2026 outlook after the canceled JenaValve deal, and a slightly higher assumed future P/E of about 33.8x.
Narrative Update • Mar 12

EW: 2026 TAVR Expansion And New LAA Closure Will Drive Upside

Our view on Edwards Lifesciences now reflects a modestly higher blended Street price target. Analysts cite updated 2026 outlooks, the canceled JenaValve deal, and expectations around TAVR indication expansion and new left atrial appendage closure products as key drivers behind their revised $90 to $108 target range.
Narrative Update • Feb 25

EW: 2026 TAVR Indication Expansion And Pipeline Progress Will Drive Upside

We are trimming our Edwards Lifesciences fair value estimate by about $0.64 per share to $96.46 as analysts balance a tighter future P/E assumption with slightly stronger margin and growth expectations, supported in part by recent research highlighting the company's pipeline progress and competitive positioning. Analyst Commentary Recent Street research around Edwards Lifesciences shows a mix of optimism on long term growth drivers and caution on competitive and execution risks, which feeds directly into how analysts are framing valuation today.
Narrative Update • Feb 09

EW: TAVR Durability And 2026 Outlook Will Shape Upside Potential

Analysts made a marginal upward adjustment to their fair value estimate for Edwards Lifesciences to about US$97.11, reflecting a series of recent price target tweaks that balance more optimistic 2026 outlooks and model updates following the canceled JenaValve acquisition, along with at least one modest target reduction. Analyst Commentary Recent research has focused on how Edwards Lifesciences' updated 2026 outlook and the canceled JenaValve deal feed into valuation, growth expectations, and execution risk.
Narrative Update • Jan 26

EW: TAVR Durability And 2026 Outlook Will Drive Renewed Upside

Analysts have nudged their fair value target for Edwards Lifesciences slightly higher to about $97 per share, reflecting modest adjustments to growth, margin, and P/E assumptions after a recent series of price target increases across Wall Street. Analyst Commentary Recent Street research around Edwards Lifesciences has tilted more positive, with several firms lifting price targets and a few moving up their ratings after company updates, product data releases, and the termination of the JenaValve acquisition.
Narrative Update • Jan 11

EW: Long-Term TAVR Durability Will Support Renewed Upside Into 2026

Our fair value estimate for Edwards Lifesciences edges up to about $96 per share, reflecting slightly higher analyst price targets. These targets are grounded in expectations for steady organic growth in TAVR, confidence in Sapien durability from long term PARTNER 3 data, and growing interest in Evoque driven opportunities into 2026.
Analysis Article • Jan 04

Edwards Lifesciences (NYSE:EW) Will Want To Turn Around Its Return Trends

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Seeking Alpha • Dec 29

The Edwards Lifesciences Dilemma Persists: Strong Growth Potential, High Price

Summary Edwards Lifesciences offers robust 10%+ revenue growth potential, but current valuation remains rich and could limit near-term upside. EW's TAVR business has reaccelerated from early in 2025, supported by new clinical data and guideline changes, and TMTT could double revenue share by 2030. Competitive risks from MDT, BSX, and ABT persist, but EW's pipeline and recent FDA approvals underpin credible long-term growth targets. I see margin expansion and free cash flow leverage ahead, yet I would await a pullback before considering new positions at these levels. Read the full article on Seeking Alpha
Narrative Update • Dec 27

EW: Long-Term TAVR Durability And Coverage Shifts Will Support Balanced Future Upside

Analysts have nudged their average price target on Edwards Lifesciences modestly higher, with fair value estimates rising to about $95.80 from roughly $95.37. They cite strong Q3 outperformance, accelerating transcatheter aortic valve replacement growth, and increased confidence in long term TAVR durability and related coverage catalysts.
Narrative Update • Dec 11

EW: Long-Term TAVR Durability Will Drive Future Low-Risk Expansion

Analysts have modestly raised their fair value estimate for Edwards Lifesciences to approximately $95 from about $94, reflecting a blend of slightly lower perceived risk, resilient high-20s profit margin expectations, and stronger confidence in long term transcatheter aortic valve replacement growth following robust Q3 results and favorable recent clinical and coverage catalysts. Analyst Commentary Street research sentiment around Edwards Lifesciences has turned more constructive, with multiple firms lifting ratings and price targets following strong Q3 execution, favorable TAVR data presentations, and improving confidence in long term growth durability.
Narrative Update • Nov 27

EW: Durable Outcomes And Low-Risk Data Will Guide Forward Opportunity And Uncertainty

Edwards Lifesciences' average analyst price target has moved higher. Increases range from $4 to $10, as analysts cite a strong Q3, upbeat guidance, and growing confidence in key clinical results as drivers for their upward revisions.
Narrative Update • Nov 12

EW: Future Progress Will Hinge On Durable Outcomes And Market Expansion

The analyst price target for Edwards Lifesciences has increased from approximately $88.83 to $93.94. Analysts point to strong quarterly results and sustained momentum in transcatheter aortic valve replacements as key drivers of the upward revision.
Narrative Update • Oct 29

Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead

Edwards Lifesciences' analyst price target has risen from $87.73 to $88.83. Analysts cite improved transcatheter aortic valve replacement data and heightened confidence in the company's long-term outlook following positive clinical results.
Analysis Article • Sep 20

Why Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth Watching

Today we're going to take a look at the well-established Edwards Lifesciences Corporation ( NYSE:EW ). The company's...
Analysis Article • Sep 05

Here's What's Concerning About Edwards Lifesciences' (NYSE:EW) Returns On Capital

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Analysis Article • Jul 16

Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$79.45 With...
Seeking Alpha • Mar 23

Edwards Lifesciences: Double-Digit Top Line And EPS Growth Ahead

Summary Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW's shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic. Technically, EW shares are rangebound with resistance at $76 and support between $67-$68, indicating potential sideways trading action. Read the full article on Seeking Alpha
Seeking Alpha • Jan 05

Edward Lifesciences: A Closer Look At Growth And Valuation

Summary Edward Lifesciences remains a "Hold" as it trades close to its intrinsic value, despite improved fundamentals and solid third-quarter results. Valuation multiples are misleading; P/E ratio is extremely low, but P/FCF ratio is high due to non-representative earnings and free cash flow. The sale of the "Critical Care" business boosted EPS, but sustainable growth stems from core segments like TAVR and TMTT, with long-term revenue growth expected at 10%. With a strong balance sheet and potential for share buybacks, Edward Lifesciences needs 14% annual FCF growth to be fairly valued; I prefer waiting for a lower price. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

Summary I reiterate my “Strong Buy” on Edwards Lifesciences Corporation, with a fair value of $85 per share, due to strategic focus on structural heart and new product investments. Edwards Lifesciences reported 9.6% organic revenue growth and a 7.2% increase in the Transcatheter Aortic Valve Replacement segment in Q3 2024. The sale of the Critical Care business for $4.2 billion will fund share buybacks, acquisitions, and strategic investments, enhancing growth in high-potential areas. Despite temporary Q4 headwinds, Edwards Lifesciences' market leadership and recent acquisitions position it well for accelerated growth in the structural heart market. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:EW - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20288,1332,1151,9342,35721
12/31/20277,4091,8911,6941,94728
12/31/20266,7141,6361,3631,60912
3/31/20266,3041,0761,0901,359N/A
12/31/20256,0681,0601,3351,595N/A
9/30/20255,8841,3428001,017N/A
6/30/20255,6851,413578795N/A
3/31/20255,5221,440623876N/A
12/31/20245,4401,401260542N/A
9/30/20245,3201,388490806N/A
6/30/20245,2091,361552866N/A
3/31/20245,1021,247251528N/A
12/31/20235,0101,223630896N/A
9/30/20235,0921,2887751,042N/A
6/30/20235,1681,296669940N/A
3/31/20235,2791,4519721,239N/A
12/31/20224,4641,3249531,218N/A
9/30/20225,3641,4591,0401,309N/A
6/30/20225,3551,4551,2611,531N/A
3/31/20225,3571,5391,4281,725N/A
12/31/20215,2331,5031,4021,732N/A
9/30/20215,0951,4771,4091,758N/A
6/30/20214,9251,4621,0501,443N/A
3/31/20214,4748517171,148N/A
12/31/20204,3868236471,054N/A
9/30/20204,3697946921,057N/A
6/30/20204,3227449411,279N/A
3/31/20204,4841,1081,0871,389N/A
12/31/20194,3481,047N/A1,183N/A
9/30/20194,152774N/A1,073N/A
6/30/20193,964725N/A978N/A
3/31/20193,821765N/A777N/A
12/31/20183,723722N/A927N/A
9/30/20183,634712N/A998N/A
6/30/20183,549657N/A966N/A
3/31/20183,447560N/A1,024N/A
12/31/20173,435584N/A1,001N/A
9/30/20173,315745N/A838N/A
6/30/20173,232716N/A733N/A
3/31/20173,150657N/A726N/A
12/31/20162,964570N/A704N/A
9/30/20162,867552N/A607N/A
6/30/20162,743528N/A604N/A
3/31/20162,601515N/A584N/A
12/31/20152,494495N/A550N/A
9/30/20152,441463N/A539N/A
6/30/20152,433440N/A349N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EW's forecast earnings growth (16.7% per year) is above the savings rate (3.5%).

Earnings vs Market: EW's earnings (16.7% per year) are forecast to grow slower than the US market (16.7% per year).

High Growth Earnings: EW's earnings are forecast to grow, but not significantly.

Revenue vs Market: EW's revenue (8.7% per year) is forecast to grow slower than the US market (11.6% per year).

High Growth Revenue: EW's revenue (8.7% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EW's Return on Equity is forecast to be low in 3 years time (16.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 06:17
End of Day Share Price 2026/05/14 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Edwards Lifesciences Corporation is covered by 55 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
Adam FeinsteinBarclays
Matthew MiksicBarclays